0001062993-18-003527.txt : 20180823 0001062993-18-003527.hdr.sgml : 20180823 20180823203631 ACCESSION NUMBER: 0001062993-18-003527 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180822 FILED AS OF DATE: 20180823 DATE AS OF CHANGE: 20180823 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wegman Mark N CENTRAL INDEX KEY: 0001405235 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 181035717 MAIL ADDRESS: STREET 1: 43 OVERLOOK ROAD CITY: OSSINING STATE: NY ZIP: 10562 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2018-08-22 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001405235 Wegman Mark N C/O BIOSPECIFICS TECHNOLOGIES CORP. 35 WILBUR STREET LYNBROOK NY 11563 1 0 0 0 Common Stock, $0.001 par value 2018-08-22 4 S 0 3802 52.7073 D 76470 D Common Stock, $0.001 par value 2018-08-23 4 S 0 4698 52.5604 D 71772 D The selling price of $52.7073 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $52.26 to $53.14. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The selling price of $52.5604 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $51.02 to $52.82. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Mark Wegman by Carl A. Valenstein, attorney- in-fact 2018-08-23